|Articles|June 10, 2010

BBK Worldwide Harnesses Apple iPad® to Support Speed-to-Market for Investigational Treatments

BBK Worldwide is introducing a Patient Recruitment Franchise Program. BBK’s flagship product for its new program is the FRANCHISE e-BINDERSM: a communication platform that uses the Apple iPad® to facilitate the myriad processes necessary to effectively recruit and manage patients for global clinical trials.

This new franchise model supports quick, efficient enrollment for multiple studies within the same therapeutic category, as well as multiple protocols for a single compound. “Franchise programs create savings through the economies of scale derived from applying strategies and tactics across multiple studies and countries,” said Joan F. Bachenheimer, BBK Worldwide founding principal and CEO. “Using the model of the Patient Recruitment Franchise Program, sponsors are able to consolidate planning and recruitment strategies for immediate and long-term cost reductions.”

The Apple iPad supports franchise-level initiatives by making it possible to instantly distribute, store, and retrieve information and data with the tap of a finger. “BBK’s application of this new technology skillfully supports clinical research professionals as they work to manage the avalanche of information surrounding clinical trial particulars,” said Matthew Stumm, BBK Worldwide creative director. Consider the following audience-specific applications of the FRANCHISE e-BINDER, powered by BBK partner company TCN e-Systems:

· Investigator meetings made simple
· Top-level data sourced and easily retrieved for clinical operations
· The STUDY MANAGER e-BINDERSM offers one-stop access to critical forms, inclusion/exclusion criteria, patient materials, etc.Can be adapted for any country/language.
· The UPDATE e-BINDERSM for clinical study managers and monitors provides a hand-held portal to site administration resources – including training, study contact listings, sponsor documentation, clinical assessment tools


Related to this article

© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.